Dermata Therapeutics closed at $0.85 on Nov 4, up 0.72%, 75.0% below its 52-week closing high. Volume of 52.0K shares was 0.01× its 20-day average (below normal).
Split-adjusted performance: -24.4% over one month, -32.7% over six months, -75.0% over one year.
Short interest was 77.3K shares at the Oct 15 settlement, down 8.5% from the prior report (2.5% of float, 1.0 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DRMADermata Therapeutics | $0.8548 | +0.72% | −32.7% | — | — | — | $4.2M | |
| TRAWTraws Pharma | $0.2686 | −11.06% | −84.2% | −100.0% | — | — | $4.1M | Compare |
| APUSApimeds Pharmaceuticals US | $2.92 | −1.68% | −85.0% | — | — | — | $4.4M | Compare |
| TCRTAlaunos Therapeutics | $1.80 | −3.23% | −31.6% | — | — | — | $4.6M | Compare |
| ONCOOnconetix | $0.6583 | +15.69% | −85.4% | −83.9% | −16748.3% | — | $3.9M | Compare |
| XBIOXenetic Biosciences | $2.01 | −3.37% | −36.6% | +12.0% | −140.7% | — | $4.7M | Compare |
| CVKDCadrenal Therapeutics | $1.06 | −6.19% | −82.8% | — | — | — | $3.8M | Compare |
| AZTRAzitra | $0.8157 | −7.71% | −66.7% | — | — | — | $4.9M | Compare |
| MDCXMedicus Pharma | $1.88 | −7.39% | −88.7% | — | — | — | $3.6M | Compare |
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
